Abstract
. Moreover, since cell transplantation also requires surgical intervention in some cases, it is desirable to explore less invasive therapeutic strategies. The [3] [4] [5] [6] and human studies [7, 8] [9] . [10] , whereas stimulation of the phosphoinosotide-dependent kinase/Akt pathway induces differentiation of stem cells. Thus, the response to specific GFs is influenced by the expression of their corresponding receptors on target cells [11, 12] .
results of the first pre-clinical and clinical studies on stem cell transplantation highlight that cell differentiation, survival and trophic cell support is promoted by growth factors (GFs). In endogenous neurogenesis, GFs induced proliferation and differentiation of adult neural stem cells from the sub-ventricular zone of lateral ventricles (SVZ) and the dentate gyrus (DG) of the hippocampus into mature neurons in both animal models

. These findings suggest that GF therapy could represent an alternative therapeutic approach to promote migration and differentiation and to enhance the survival of endogenous stem cells by modulating pathways of endogenous neurogenesis. Experimental studies show that hematopoietic GFs can improve stroke outcome through their pleiotropic effects which include neuroprotection, stem cell survival and promotion of angiogenesis and neurogenesis, as well as through their antiapoptotic and anti-inflammatory effects
Most GFs act binding specific receptors activating different signalling pathways and inducing the expression of specific genes involved in cell proliferation and differentiation. For instance, receptor-mediated activation of the mitogen-activated protein kinase (MAPK) promotes proliferation
This review provides a critical, up-to-date evaluation of the literature relevant to the role of select GFs in post-stroke recovery. Both experimental models and human studies of ischemic stroke are included and discussed.
Search strategies
We included studies (abstracts, letters, articles, case-control studies, reviews and meta-analyses) on experimental models of stroke and in human beings. Our search focused on the GFs most often studied in ischemic stroke. The literature search included articles from 1960 to October 2009 in electronic bibliographic databases (MEDLINE, EMBASE). Reference lists from primary and review articles, and the MEDLINE function 'related articles' were also consulted. As search key words, we used: granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor (SCF), vascular endothelial growth factor (VEGF), stromal cell-derived factor-1␣ (SDF-1␣) and insulin growth factor-1 (IGF-1)
, and ischemic stroke, stroke, cerebrovascular disease and stem cell transplantation. Finally, we also examined non-English articles and studies on haemorrhagic stroke.
Haematopoietic growth factors
Red cells, granulocytes, monocytes, platelets and lymphocytes all derive from a common multipotent bone-marrow stem cell. Haemopoietic GFs, also known as CSFs, modulate lineage-specific differentiation of bone marrow stem cells (BMSCs), leading to the generation of circulating red cells, white cells and platelets.
Data from experimental studies (Table 1 ) support the notion that CSFs could improve stroke outcome by reducing stroke damage and improving post-stroke brain repair [9] .
Granulocyte colony-stimulating factor
Human G-CSF is a 19.6 kD glycoprotein encoded by a single gene located on chromosome 17q11-12 [13] . G-CSF contains a hydrophilic signal sequence [14] , which is responsible for the mobilization and proliferation of BMSCs, leading to their differentiation in circulating neutrophilic granulocytes. Two variant forms of this protein can be derived from differential splicing of the G-CSF mRNA [15] . G-CSF is produced, above all, by activated monocytes in response to inflammatory cytokines [16] , but also by endothelial cells, fibroblasts, mesothelial cells and platelets [17] . [18] [19] [20] [21] [22] [29] [30] [31] [32] . Activation of these pathways mediates proliferation, differentiation and survival of hematopoietic cells [33] . [72] .
Tumour necrosis factor (TNF)-␣, interleukin (IL)-1, GM-CSF, IL-4 and bacterial lipopolysaccharide could induce G-CSF production in vitro
. G-CSF functions as a stimulating factor after binding to its receptor (GCSF-R), which is a type I membrane protein consisting of four different domains; an immunoglobulin-like domain, a cytokine receptor-homologous domain and three fibronectin type III domains in the extracellular region [23]. G-CSFR is expressed not only by haematopoietic cells (neutrophils, platelets, lymphocytes and monocytes), but also by endothelial cells, neurons and glial cells [24-28]. GCSF-R activates a variety of intracellular pathways, including the Janus kinase (JAK)/signal transducer and activator of transcription (STAT), the Ras/MAPK and phosphatidylinositol 3-kinase (PI3K)/protein kinase B
The pharmacological effects and side effect profile of G-CSF are well known, since recombinant G-CSF is a licensed drug commonly used in clinical practice to treat chemotherapy-induced neutropenia and to boost stem cell mobilization in bone-
G-CSF and experimental stroke
In vitro, G-CSF was reported as being neuroprotective in cell cultures exposed to glutamate-induced excitotoxicity [35] and to promote neuronal differentiation [36] G-CSF was identified as having trophic effects on different cell types within the central nervous system (CNS) and to induce neuroprotection during recovery after brain injury [37]. Endogenous G-CSF seems to play an important role in the brain's response to ischemia. G-CSF and its receptor are expressed in response to ischemia in the penumbral region of ischemic stroke [36] where it has an anti-apoptotic effect, resulting in reduced cell death in the ischemic penumbra [36, 38, 39]. Data from a post-mortem study demonstrated a strong neuronal G-CSF and GCSF-R immunoreactivity in the infarct and peri-infarct areas in both acute and subacute stroke. Neuronal G-CSF was expressed as a very early response to ischemic stroke, whereas in the subacute phase it was predominantly up-regulated in vascular cells [40]. A clear demonstration of the role of endogenous G-CSF in response to brain ischemia comes from the detection that G-CSF-deficient mice are prone to develop larger infarcts and have worse clinical outcome, and that these effects were reversed after G-CSF administration. In the same study, both real time PCR and immunohistochemistry detected an up-regulation of matrix metalloproteinase 9 (MMP-9), proteins that are normally present in the brain in latent form and that, once activated, contribute to the injury process through neurovascular matrix degradation and increased vascular permeability [41]. This finding also supports a role for GF in the endogenous response to ischemic brain damage [42-44]. In an animal model of permanent as well as transient middle cerebral artery occlusion (MCAO), G-CSF produced a significant reduction in brain oedema partly mediated by suppression of injury-induced up-regulation of IL-1, TNF-␣ and endothelial nitric oxide synthase (eNOS) mRNA [45]. Blood brain barrier (BBB) damage is probably prevented by the decreased production of pro-inflammatory cytokines, the resulting T-cell infiltration [46, 47], and by up-regulation of anti-inflammatory molecules
G-CSF and human stroke
A [73] .
multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase IIA trial (AXIS) was recently completed. In the 45 acute stroke patients in this trial, G-CSF was safe, well-tolerated and showed clinical efficacy, even in patients with wide baseline lesions detected by diffusion-weighted imaging (DWI)-MRI
Ongoing studies
A phase IIB/IIIA trial (AXIS), that will start in the second quarter of 2009 [74] , and the Regeneration in Acute Ischemic Stroke Study, were implemented to confirm the safety of G-CSF administration in acute stroke patients [75] . [76] . Human EPO is encoded by a single gene consisting of 5 exons located on chromosome 7 [77] . Gene expression is controlled by an oxygen-sensing, hypoxia-inducible factor-dependent mechanism [78] . EPO [79] was shown to increase transcription of cyclins, inhibit cell-cycle inhibitors and to increase the concentration of the anti-apoptotic protein, BCLXL [76, 80] [81] [82] [83] . In addition to renal and liver tissues, EPO is also expressed in many extra-renal tissues in cell types such as astrocytes [84] , neurons [85] and bone marrow macrophages [86] . It functions as a stimulating factor by binding to a specific erythropoietin receptor (EPOR), a member of the cytokine type 2 family [87] [88] [89] [90, 91] .
The phase I, granulocyte colonystimulating factor in ischemic stroke trial is also ongoing to verify the mortality and adverse effects of G-CSF therapy as the primary end-point (www.clinicaltrials.gov, NCT00809549). Another phase II clinical trial currently recruiting patients was implemented to assess whether s.c. G-CSF and erythropoietin administration (EPO) influence associative learning and/or motor skills in patients who experience chronic stroke or amyotrophic lateral sclerosis (www.clinicaltrials.gov, NCT00298597).
Current evidence and future perspectives Endogenous G-CSF plays an important role in brain response to ischemia. G-CSF administration in animal models is associated with reduced infarct volume, decreased mortality and better clinical outcome. Recombinant G-CSF is already approved for limited clinical use in human beings. G-CSF administration in stroke patients was safe, but further studies should be implemented in order to demonstrate its efficacy.
Erythropoietin
EPO is a protein hormone of about 34.4 kD and a member of the class I cytokine family
, favouring red cell proliferation and promoting the differentiation of bone-marrow stem cells into circulating mature red cells. It is produced by renal interstitial cells in the peritubular capillary beds of adult kidney, and by liver perivenous hepatocytes
The EPOR is widely expressed in non-erythroid cells and tissues such as smooth muscle cells [92] , myoblasts [93] , vascular endothelium [94] , heart [95] , kidney [96] , neuronal cells [97, 98] and brain [99] . [91] including the PI3K and extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathways [100] [101] [102] . Activation of these pathways prevents apoptosis of late erythroid progenitors by promoting their survival, proliferation and differentiation [102] . In human beings, EPO also enhances megakaryocyte maturation by augmenting platelet counts by 10-20% and increasing platelet function [103, 104] .
EPOR dimerizes upon EPO binding, which increases the receptor's affinity for JAK2 in the membrane proximal region of the receptor. This results in JAK2/STAT5 protein phosphorylation and activates other signal transduction pathways
EPO administration is associated with proliferation of erythroid progenitor cells, which, once differentiated into normoblasts, enucleate and leave the bone marrow [17] . Recombinant [106, 107] .
EPO and experimental stroke
EPO and EPOR are constitutively expressed in the central nervous system and play a significant role during brain development [108] . In neurons, EPO and its receptor activate multiple signal transduction pathways including STAT, PI3K/Akt, Ras/ERK1/2, nuclear factor-kB (NF-kB) and intracellular calcium levels [89] . [109, 110] as well as on cortical neurons [111, 112] [110] [111] [112] [113] . EPOR up-regulation occurs first in neurons and endothelial cells in microcirculation after 12 hrs, and is later observed in both neurons and astrocytes. This phenomenon is prominently observed in the penumbra area [85] .
EPO is neuroprotective in cell cultures. This results in a protective and anti-apoptotic effect on hippocampal neurons
The evidence that endogenous EPO inhibition results in more severe brain damage [89] and that EPOR-deficient mice shows increased sensitivity to hypoxia and increased brain apoptosis [91] further support EPO's major role in the brain's response to ischemia. Hypoxia-induced EPO expression is mediated by hypoxia inducible factor (HIF), which may be involved in ischemic tolerance [114] .
The anti-apoptotic effect of EPO was shown in different animal models. Studies from neonatal rat and mouse stroke models in showed reduced apoptosis through the differential regulation and expression of genes involved in the apoptotic process [115] [116] [117] [118] .
A similar anti-apoptotic effect was observed in a gerbil model of cerebral ischemia [119, 120] . Villa et al. [120] [121] . EPO administration was also shown to be associated with improved outcome in an experimental model of traumatic brain injury and with reduced brain oedema [122] . A recent paper showed that EPO reduces neurological symptoms in a mouse model of primary brain oedema [123] 
reported a significant reduction in astrocytes, leucocytes and microglia activation as well as decreased production of pro-inflammatory cytokines like TNF-␣, IL-6 and monocyte chemoattractant protein 1 in the ischemic area of a MCAO rat model. The same authors reported a similar anti-inflammatory effect consisting of reduced cellular infiltration, apoptosis and white matter damage after treatment with a non-erythropoietic EPO derivate (CEPO) in a rat model of focal cerebral ischemia
supporting the evidence that an important component of EPO's neuroprotective function may be its role in modulating astrocyte water permeability through the regulation of intracellular calcium oscillations, reducing the risk of astrocyte swelling during stroke and other brain insults.
In addition to its anti-apoptotic and anti-oedema effects, EPO exerted pleiotropic effects as an antioxidant [124, 125] , anti-inflammatory [120] [121] [122] [123] [124] [125] [126] , glutamate-inhibitory [127] , neurotrophic [128] and angiogenic [88] factors, and influenced stem cell differentiation [88, 91, [129] [130] [131] .
A [132] .
Interestingly, it has been described that the receptors that mediate the neuroprotective effect after ischaemic and traumatic brain injury [133, 134] are different from those expressed by erthroid precursors, [133] and also several EPO variants that do not bind to myeloid cells have a neuroprotective effect [135, 136] [140] . It is a 127 amino acid protein, a member of the haematopoietin receptor superfamily, consisting of cytokine-specific ␣ and common ␤ chains [141] . Other than being responsible for the in vitro stimulation of myeloid precursor clonal proliferation [142] , GM-CSF was shown to be involved in neutrophils, monocytes, dendritic cell and in macrophage survival and differentiation [143] . [144] . [145] . GMCSFR [146, 147] . [148] . Trials have also been conducted to assess GM-CSF use in sepsis, drug-induced neutropenia, HIV infection, acute myeloid leukaemia, aplastic anaemia, myelodysplasia [148] and recently as adjuvant therapy for indolent B-cell lymphoma [149] , cutaneous melanoma [150] and chronic lymphocytic leukaemia [151] . The most common dose-related adverse effects are bone pain, erythroderma, weight gain, oedema and inflammation [152] .
Granulocyte-macrophage colony-stimulating factor
Human GM-CSF is a 22 kD glycoprotein encoded by a single gene located on chromosome 5q21-5q32 near the IL-3, IL-4, IL-5, IL-9 and MCSF-R genes
GM-CSF is produced by different cell types such as T and B lymphocytes, macrophages, keratinocytes, eosinophils, neutrophils and endothelial cells [144]. GM-CSF function is mediated by activation of the GM-CSF receptor (GMCSFR) which is a cytokine belonging to the type I receptor group. The ␣-chain of GMCSFR is specific for binding GM-CSF, whereas the ␤ subunit is involved in signal transduction
GM-CSF binding to its receptor regulates cell proliferation through activation of the JAK2/STAT5 and MAPK pathways, but also regulates apoptosis and cell survival through activation of the JAK/STAT and PI3K/Akt pathways
The recombinant form of GM-CSF is recognized as a treatment for chemotherapy-induced neutropenia and also employed to enhance the antiviral effects of azidothymidine in HIV patients
Increased levels of the pro-inflammatory cytokines IL-8 and GM-CSF were found in the cerebrospinal fluid (CSF) of patients on day 2 after stroke [153] , supporting the evidence of a focal immune response in ischemic brain [154] .
GM-CSF and experimental stroke
The GMCSFR is broadly expressed in brain regions with a predominantly neuronal pattern in neurons of DG and SVZ [155] . [156] .
To our knowledge, there are no published studies investigating the neuroprotective effect of endogenous GM-CSF in GM-CSF deficient mouse models. RT-PCR studies reveal that it is expressed in cultured adult stem cells as well as in rodent brain, and that it can enhance neuronal differentiation in adult stem cells in a dose-dependent manner
GMCSFR ␣ gene expression is induced by brain ischemia [155] . Nakagawa et al. [157] [167] . VEGF is ubiquitously expressed in brain, mostly by choroid plexus epithelial cells but also by astrocytes and neurons [169, 170] .
Many different factors, including both genes and gene products, are known to enhance VEGF production. VEGF is secreted by tumours in response to hypoxia to stimulate angiogenesis to increase oxygen supply [171] , but its production is also triggered by oncogenes (c-Src, Bcr-Abl and Ras oncogenes), tumour suppressor genes (e.g. p53) [172] [173] [174] [175] 
VEGF and experimental stroke
In vitro, VEGF protects cultured motor neurons from hypoxia, reactive oxygen species, and glutamate-induced toxicity [181, 182] and acts as a trophic factor for neuronal stem cells [183] . Moreover, VEGF and VEGFR expression were induced in brain after global ischemia [184] or permanent [185] or transient MCAO, with a different temporal profile among these cells [186] [187] [188] .
In hypoxic and ischemic brain, VEGF expression is induced by transcriptional activation via HIF-1 and HIF-2 [170, 185, 189, 190] . Within 6 hrs after ischemic injury, VEGF expression was increased in the penumbra area [185] . VEGF, VEGFR2 and HIF-1, through their angiogenic functions, seem to be protective in long-term responses to hypoxic injury, even if, in the acute phase, their expression favours oedema formation [191] .
VEGF-A was also expressed during hypoxic preconditioning in adult mouse [192] . Immunohistochemistry of brain tissue from adult rats subjected to photothrombotic ring stroke with spontaneous reperfusion showed that the VEGF protein subtypes A and C increased simultaneously 2 hrs after irradiation of the lesion, and from 24 to 72 hrs after stroke in the penumbra-like zone. The expression of VEGF A, C, and their respective receptors (flt-1, flk-1 and flt-4) was also associated with microvessel formation [193] . Since VEGF plays a positive role in angiogenesis, remodelling and re-vascularization of damaged tissues [191] GF has recently been under investigation in ischemic brain [194] . eNOS expression after brain ischemia following permanent MCAO was found to temporarily and anatomically co-localize with VEGF expression mostly in the penumbra area where these proteins probably exert a protective effect on damaged brain tissue [195] . Furthermore, in a rat model of focal embolic cerebral ischemia, exogenous nitric oxide administration was shown to enhance angiogenesis and vasculogenesis by activating the nitric oxide/cyclic guanosine monophosphate pathway and by increasing VEGF levels in ischemic boundary regions [196] . Mice overexpressing the human VEGF165 isoform exhibited a physiologically higher density of brain vessels and enhanced angiogenesis after brain ischemia. Mice overexpressing VEGF also had a smaller infarct area, which correlated with better clinical outcome [197, 198] .
VEGF overexpression was associated with a higher capillary density, but not with an increase in blood flow, probably because circulating blood is stolen by the non-ischemic areas [197] . [199] .
Another experimental model in which recombinant human VEGF165 was infused into the right lateral ventricle of rats 1 week before MCAO showed that VEGF was able to decrease infarct volume and brain oedema without increasing CBF
Several experimental studies substantially confirmed the positive effect of VEGF in ischemic stroke. Transient MCAO is the most common model despite a great deal of variability between different protocols in terms of the administration route (see Table 1 ).
VEGF administration, as previously reported for other GFs, was associated with an infarct size reduction ranging from 34% to 47% [199] [200] [201] [202] and improved clinical outcome [198, [202] [203] [204] [205] without an increase in brain oedema [199, 202] [203] .
. The relationship between VEGF and brain oedema has been investigated by studies aimed at clarifying the possible underlying mechanisms of brain oedema. The evaluation of VEGF and angiopoietin (Ang-1 and -2) expression in a rat model of irreversible MCAO by Beck et al. [206], showed that, in the early phase after ischemic damage, Ang-2, which plays a role in vascular remodelling by blocking the constitutive expression of Ang-1, is hypoxia induced. Thereafter, Ang-2 expression is likely to follow VEGF up-regulation, since VEGF protein was first detected after 6 hrs with expression peaking after 24 hrs [206]. The combined effects of VEGF and Ang-2 on cerebral angiogenesis was confirmed by Zhu and colleagues, who also reported that Ang-2 and VEGF act in combination in BBB disruption [207]. This effect on the BBB was previously reported in a rat model of focal cerebral ischemia in which MRI) showed that post-ischemic (1 hr) administration of rhVEGF165 significantly increases BBB leakage, haemorrhagic transformation and ischemic lesions, whereas VEGF administration after the acute phase (48 hrs) was associated with angiogenesis enhancement and functional improvement
The link between VEGF and BBB after stroke was further investigated by Zhang et al. in a rat model of embolic stroke where VEGF mRNA was found to be increased 2 to 4 hrs after stroke, whereas Ang-1 mRNA decreased [208] . [206] [207] [208] . Zhang [210] . [212] . In a 90-min. [201] . [213] . [215] . [217] . [218] . [205] . [200] . [221] [222] [223] [224, 225] . In brain, SDF-1/CXCR4 is recognized as being expressed in a variety of neuronal tissues during development, including cerebellum [226] , cerebral cortex [227, 228] , DG [229] and motor axons [230] , where it was shown to regulate synaptic transmission and neural cell migration [231, 232] and to guide migration of neural progenitors from the external germinal layer to the internal granular layer [233] [234] [235] . [245] . Stumm et al. (2002) [246] .
There was an association between VEGF up-regulation and BBB leakage in the ischemic core. VEGF/VEGFRs and Ang/Tie2 were detected at the boundary of the ischemic lesion from two to 28 days after stroke in association with newly formed vessels. These data support a possible role of Ang-1 in limiting VEGF-induced BBB leakage during the acute phase, whereas up-regulation of VEGF/VEGFR and Ang/Tie2 at the boundary zone may regulate neovascularization and angiogenesis in ischemic brain tissue
and Chopp administered exogenous VEGF in a mouse model of focal cerebral ischemia showing that increased levels of Ang-1 reduces BBB leakage [209]. Mesenchymal stem cell (MSC) infusion 24 hrs after MCAO significantly decreased BBB leakage and promoted angiogenesis by increasing endogenous Ang1 and Tie2, and occluding cerebral expression in the ischemic border. Capillary formation was reduced after inhibition of Flk1 or Ang-1 and down-regulation of Tie-2, suggesting a critical role for VEGF/Flk1 and Ang1/Tie2 in MSC-induced angiogenesis
In a mouse model of brain ischemia, inhibition of VEGF activity using a neutralizing antibody was shown to completely block hypoxia-induced vascular permeability [211]. A similar effect was obtained by employing the VEGF antagonist in a rat model of vasogenic oedema due to cerebral venous ischemia
MCAO rat model, pre-treatment with a KDR kinase inhibitor elicited an early, transient decrease in oedema and subsequent reduction in infarct volume, implicating VEGF as a mediator of stroke-related vascular permeability and ischemic injury
The role of VEGF in stroke-oedema is confirmed by further experimental models. Stereotactic injection of VEGF into the left substantia nigra (SN) resulted in highly up-regulated aquaporin-4 (AQP4), which is the most abundant water channel in the brain. AQP4 mRNA and protein in the ventral midbrain localized in close proximity with the new VEGF-induced blood vessels suggest a positive role of AQP4 in oedema resolution, which may partially explain the previously reported beneficial effects of delayed VEGF administration in ischemic rats
In a gerbil model of focal brain ischemia, pre-treatment (6 days or 12 days) with an intracerebroventricular injection of adenoassociated virus transferring the gene for VEGF (rAAV-VEGF) improved survival and brain oedema, and delayed neuronal death [214]. However, this method of administration is controversial with some authors reporting that intraventricular rAAV-VEGF pretreatment in the transient MCAO rat model can result in deleterious intracranial hypertension and augment secondary ischemic insults during the early stages. They concluded that pre-ischemic VEGF gene transfer via an intraventricular approach may not be a favourable therapeutic strategy for MCAO, which should be adopted with caution or avoided in experimental stroke
Also, different dosages of VEGF165 can injure rather than promote recovery of nervous tissue [216]. In this experimental model, VEGF165 was administered intra-arterially at different dosages in temporary MCAO rats. In this study, brain treated with low non-angiogenic doses of VEGF165 showed preserved neuropils and reduced numbers of macrophages in comparison with ischemic brains treated with high angiogenic doses, which showed phagocytized neuropils and a high macrophage density. Both HIF-1␣ and VEGFR-2 were implicated in peri-infarct neuroprotection. In squirrel monkeys, a bipolar electro-coagulation of cortical vessels supplying the M1 hand area representation was performed. It was shown that HIF-1a up-regulation was confined to the infarct and peri-infarct regions. Increases in VEGFR-2 immunoreactivity occurred in two remote regions. Thus, while remote areas undergo a molecular response to the infarct, the authors suggested that there is a delay in the initiation of the response, which may ultimately increase the 'window of opportunity' for neuroprotective interventions in the intact cortex
Regarding new insights in VEGF mediated angiogenesis, MCAO was performed in mice overexpressing (VEGF-hi/ϩ) and underexpressing (VEGF-lo/ϩ) VEGF. Compared with VEGF-hi/ϩ mice, VEGF-lo/ϩ mice formed fewer collaterals during the perinatal period when adult density was established, and had a 2-fold larger infarction after MCA ligation, suggesting that VEGF and VEGFR-1 are determinants of arteriogenesis. VEGF-A specifies formation of native collaterals in healthy tissues
In cerebral ischemia, Chu et al. investigated the effects of combined intravenous administration of transplanted neural stem cells and VEGF on focal cerebral ischemia in rats. Combined cell and pharmacological therapy was associated with better functional recovery (improved sensorimotor deficit and better performance on the behaviour tests), reduced cerebral atrophy and increased vascular density without a significant effect on stem cell survival
VEGF and human stroke
No clinical studies with VEGF have been implemented so far in ischemic stroke patients.
Ongoing studies
One study is active but not ongoing. It focuses on angiogenesis after intracardiac injection of VEGF (phase I) and oral L-arginine supplementation (phase II) in coronary artery disease patients. This study could provide useful information on the effects of VEGF on angiogenesis after ischemic injury (www.clinicaltrial.gov, NCT00134433).
Current evidence and future perspectives
VEGF is a trophic factor for neuronal stem cells and its expression increases after cerebral ischemia. In animal models, VEGF administration results in better functional outcome and reduced infarct size and oedema. Currently there are no data from studies assessing the safety and efficacy of VEGF in stroke patients.
Stromal cell-derived factor-1
SDF-1 is a CXC chemokine produced by bone marrow stromal cells. Two isoforms, SDF-1␣ and SDF-1␤, arising from alternative splicing of the SDF-1 mRNA, are identified. The resulting proteins, SDF-1␣ and SDF-1␤ are identical except for four C-terminal amino acids and represent endogenous ligands for the CXC chemokine receptor 4 (CXCR4), which also functions as co-receptor for HIV-1 in lymphocytes
The detection of increased SDF-1␣ expression in the brain of HIV-positive patients supports the notion that SDF-1␣ may also play a role in neuroprotection and neuronal plasticity [236]. SDF-1 up-regulates the expression of VEGF in neurovascular endothelial cells [237]. In addition, the SDF-1␣/CXCR4 axis is related to arginine vasopressin release in adult brain [238-240] and microglia-enhanced, SDF-1-stimulated, TNF-␤ and glutamate release from astrocytes in vitro. This mechanism is also proposed as a novel excitotoxic pathological mechanism in some neurodegenerative diseases [241]. Expression of both SDF-1␣ and CXCR4 was up-regulated, mostly under hypoxic conditions such as acute renal failure, ischemic cardiomyopathy and ischemic brain injury [242-244]. Liu et al. reported that synchronized Ca 2ϩ spikes among cultured hippocampal neurons, which represent periodic burst firing of action potentials believed to play a major role in the development and plasticity of the neuronal circuitry, can be modulated by two small factors that act on G-protein-coupled receptors (GPCRs): the neuropeptide pituitary adenylate cyclase-activating polypeptide, and the chemokine SDF-1. This modulation of neuronal activity through GPCRs may represent a significant mechanism that underlies the neuronal plasticity during neural development and functioning
demonstrated that an isoform-specific regulation of SDF-1, obtained by alternative splicing, modulated neurotransmission and cerebral infiltration through distinct CXCR4 pathways. After focal ischemia, SDF-1␤ expression increased in the endothelial cells of the penumbra blood vessels and decreased in non-lesioned brain areas, whereas there was concomitant infiltration of CXCR4-expressing peripheral blood cells. In the same experimental model, neuronal SDF-1␣ was transiently down-regulated and neuronal CXCR4 was transiently up-regulated in the nonlesioned cortex after ischemia. Thus, whereas SDF-1␤ may control cerebral blood cell infiltration, the neuronal SDF1-␣/CXCR4 system may contribute to ischemia-induced neuronal plasticity, suggesting that the isoform-specific regulation of SDF-1 expression modulates neurotransmission and cerebral infiltration
SDF-1 in experimental stroke
Stumm et al. [246] [242, [248] [249] [250] [251] [252] [253] . CXCR4 was identified in tissue-committed bone marrow stem cells, which express neural lineage markers and may become attracted to ischemic brain tissue via SDF-1 [254] . [256] .
The extended expression of SDF-1 in the penumbra, and at a later time in the ischemic core when new blood vessels are forming, is concordant with its being involved in some aspects of brain remodelling following ischemic injury. Thus, there is considerable evidence for SDF-1s having a role in targeting neuronal precursors as well as neural and bone marrow-derived MSC towards an ischemic brain lesion
The role of this chemokine as a signal adhesion molecule and in inducing migration of HSCs to injured brain tissue in an ischemic animal model was further demonstrated by Shyu et al. [255]. These authors injected recombinant SDF1␣ protein intracerebrally into MCAO rats and treated cells in culture with SDF-1. This treatment increased engraftment of BrdU-labelled bone marrow derived cells in the ipsilateral cortex near the ischemic area boundary and in the sub-ventricular region of the ischemic hemisphere. The same authors performed an intracerebral injection of human olfactory ensheathing cells (OECs)/olfactory nerve fibroblasts (hOECs/ONFs) in a stroke model. Transplanted and endogenous homing stem cells co localized with specific neural and vascular markers, suggesting a stem-cell fusion phenomena. Interestingly, both hOECs/ONFs and endogenous homing stem cells enhanced neuroplasticity in rat and mouse ischemic brain models by up-regulation of SDF-1␣ and CXCR4
A great increase in SDF-1 and CXCR4 expression in the infarct and peri-infarct regions 2-10 days after stroke was also recently reported by Schonemeier et al. [257] [258] . [260] . The same authors demonstrated a beneficial effect of SCF treatment in an animal model of chronic brain ischemia [260, 261] [261] . [262] .
Stem cell factor
SCF is an essential haematopoietic cytokine that interacts with other cytokines to preserve the viability of hematopoietic stem and progenitor cells, influencing their entry into the cell cycle and facilitating their proliferation and differentiation. When combined with other cytokines, SCF increases the cloning efficacy of hematopoietic progenitor cells from all lineages and the clonogenic activity of other CSFs
SCF alone cannot drive non-cycling haematopoietic progenitor cells into the cell cycle, but can prevent these cells from undergoing apoptosis. Particularly, SCF and G-CSF favour neurogenesis and have a neuroprotective effect partly mediated by up-regulation of anti-inflammatory cytokines such as IL-10 [61]. Moreover, SCF plus G-CSF augment bone marrow derived cells that express the neuronal marker, NeuN in intact brains [259] as well as in acute and subacute ischemic brains [59]. The combined use of these GFs also supports the mobilization of BMSCs into the brain and their differentiation into neuronal cells. SCF and G-CSF administration, in the acute phase after focal ischemia induced by permanent MCAO, was associated with infarct volume reduction [59]. In a rat model, SCF administered in the acute phase and within the 7 days after experimental stroke was associated with enhanced neuronal progenitor cell proliferation, reduced infarct size and improved clinical outcome. In this study, functional improvement was delayed in SCF-treated animals, but was long lasting compared with G-CSFtreated animals
Current evidence and future perspectives
Other growth factors: neurotrophins
It has been observed that cerebral ischemia up-regulates expression of several GFs such as brain-derived neurotrophic factor (BDNF), fibroblast growth factor (FGF)-2 and IGF-1, epidermal growth factor (EGF) and glial cell line-derived neurotrophic factor (GDNF)
Neurotrophins are a family of structurally related polypeptides that play a critical role during neuronal development and appear to mediate a protective response in mature animals [263] . [264] [265] [266] [267] . hMSCs respond to the ischemia-injured brain environment through an increased production of neurotrophins and angiogenic factors [268] . [270] . BDNF is also related to synaptic and axonal plasticity associated with memory, learning and sensory-motor improvement [271, 272] . It also increases the number of neurons in newborns and induces neurogenesis [273] [274] [275] . With regard to these findings, BDNF knockout mice developed larger infarcts, and blockade of endogenous BDNF reduced the survival of neurons after an ischemic insult [276, 277] . Intrastriatal infusion of BDNF in adult rats before ischemia induced increased neuronal survival and improved functional recovery [278] .
Neurotrophins demonstrated a protective role in several experimental stroke studies (Table 2). Human mesenchymal stem cells (hMSCs) have the capacity to secrete neurotrophins in culture
Brain-derived neurotrophic factor
BDNF, a member of the nerve growth factor (NGF) family, is the most abundantly expressed neurotrophin in the mature CNS. It acts through a high-affinity cell surface receptor (TRKB) [269], supports the survival of many types of neurons and prevents neuronal death after traumatic events like cerebral ischemia by activating intracellular protein kinases B, MAPKs and ERKs
Ferrer et al. [279] [287, 288] . Preliminary experimental studies showed up-regulated expression of FGF in brain after ischemic injury [289] . Additionally, bFGF is implicated in neurogenesis; after endogenous administration of FGF, cells co localize with neurons and markers of proliferating cells such as BrdU and NeuN [290] .
Intravenous administration of high doses of bFGF within hours after stroke onset reduces infarct size (24-50% reduction of infarct volume) in animals subjected to MCAO [291] , showing that intravenous bFGF crosses the damaged BBB [292] . These effects were confirmed by Li et al. [293] , who showed that infusion of bFGF 2 hrs after stroke onset significantly improved sensorimotor functions and reduced infarct volume. Although the mechanism of neuroprotection by intravenous bFGF is unclear, it is supposed that it is related to a direct cytoprotection of the cells in the penumbra area [293] . [295] or in ischemic rats by MCAO occlusion [296] showed that this combined treatment further increases ischemia-induced endogenous neurogenesis and cell maturation. Also, administration of BMSCs engineered to produce FGF2 [297] and recombinant adenovirus vector expressing FGF2 decreased infarct size [298] , supporting a neuroprotective role and a neurogenesis-stimulating property for this GF, taking advantage of a less invasive administration method. [302] . Circulating IGF-1 can cross the BBB [303] [304] [305] [306] and modulates brain function in many different ways [306] [307] [308] . It is a well known angiogenic factor [309] that also plays an essential role in normal growth and brain development [310] , other than in modulation of vessel formation during brain development [311] , and possibly in age-related changes in the brain vasculature [312] . It was also reported to enhance endothelial function through its antiinflammatory and anti-apoptotic properties [313] .
Current evidence and future perspectives
In past years, it was supposed that both brain-derived and circulating IGF-1 acted as a neuroprotective signal against acute ischemic brain injury [314, 315] . Actually, the role of IGF-1 in ischemic stroke is controversial, even in consideration of the wide variability of serum IGF-1 levels among individuals [316] . For instance, serum IGF-1 levels in human beings may be depressed after acute stroke [314, 315] , whereas increased IGF-1 levels have been detected proximal to ischemic lesions in rodent models [317] , suggesting a protective role of IGF-1 [302] . Many later studies showed that IGF-1 administration protects adult brain from experimental ischemia [318] [319] [320] [108, 155] and are upregulated in response to brain ischemia [36, 40, 110, 113, 184, 242, 246, 247] [88-91, 129, 131] . Additionally, EPO regulates the expression of genes involved in apoptosis [115] [116] [117] [118] , to reduce the production of pro-inflammatory cytokines [120] and brain oedema [123] . GM-CSF results in with improved brain hemodynamic parameters [161] , favours proliferation and structural changes in intraparenchymal vessels after stroke [158, 163] , enhances leptomeningeal collateral growth [163] and counteracts metabolic damage subsequent to hypotension [162] . In addition to this, GM-CSF administration results in a positive modulation of apoptosis-related genes leading to a significant decrease in neuronal apoptosis [155, 160] . VEGF and its receptor (VEGFR-2) play a significant role in the initial phase of angiogenesis. Angiopoietins are involved in the maturation, stabilization and remodelling of vessels, and VEGF overexpression resulted in a higher capillary density but not a corresponding increase in blood flow [199] . Moreover, VEGF counteracted apoptosis and reduced brain oedema.
Taken together, the results of pre-clinical studies show that bEGF, VEGF, G-CSF, EGF, FGF-2, IGF and GDNF [343, 334] are upregulated after ischemia [294, 317, [347] [348] [349] [350] [138, 139] involving patients with hyperacute stroke (treatment within 8 hrs of symptom onset) reported a positive, but insignificant [138] [200, 203] . However, IGF-1 was not beneficial in the acute phase [302] . With regard to G-CSF, a few pre-clinical studies [261, 352] 
